A preformulation co-crystal screening case study: Polymorphic co-crystals of an imidazopyridazine antimalarial drug lead with the coformer succinic acid

Terence J. Noonan,Kelly Chibale,Susan A. Bourne,Mino R. Caira

DOI: https://doi.org/10.1016/j.molstruc.2019.127561

IF: 3.841

2020-03-01

Journal of Molecular Structure

Abstract:<p>A crystal engineering approach combined with experimental screening methods was employed as a preformulation step for producing expectedly useful forms of a novel antimalarial drug lead (MMV652103). In previous experiments, this drug lead had shown promise both <em>in vitro</em> and <em>in vivo</em> against the human malaria parasite <em>Plasmodium falciparum</em>. Various new forms of MMV652103 were produced earlier, including co-crystals, a salt, polymorphs and a hydrated form and these were reported elsewhere. Three distinct new forms are reported here, of which two are conformational and synthon (2:1) co-crystal polymorphs produced with the coformer succinic acid, while the third is a co-crystal with a different stoichiometric ratio (1:1) of the same components. The crystal structures of the co-crystal polymorphs were elucidated by single-crystal X-ray diffraction. The different forms were also characterised by powder X-ray diffraction, Fourier transform infrared spectroscopy, ¹H nuclear magnetic resonance spectroscopy, hot stage microscopy, differential thermal analysis, differential scanning calorimetry, thermogravimetric analysis and in some cases variable-temperature powder X-ray diffraction. It was determined that the polymorphs are monotropically related. Methods were developed to prepare each of these forms reproducibly and rapidly identify each form.</p>

chemistry, physical